AbbVie Hits Phase 3 Cancer Trial Milestone, Triggers $10M Payment to Nxera

Key Facts

In a move that strengthens its position in the biopharmaceutical sector, AbbVie announced a Phase 3 victory for its drug epcoritamab in treating relapsed/refractory DLBCL, meeting its primary efficacy endpoints. Following this clinical success, AbbVie triggered a $10 million milestone payment to Nxera as part of their ongoing neuro-focused R&D collaboration. According to reports, this latest payment brings the total milestones for 2022 to $40 million, within a partnership that holds a potential total value of $1.2 billion in future payments.

This clinical milestone arrives amid intensifying competition in the oncology market, where AbbVie vies for market share against giants like Roche and Bristol Myers Squibb. Per market data, successful Phase 3 results are a critical precursor to regulatory filings and commercial scaling, potentially securing long-term revenue streams. The collaboration with Nxera further highlights AbbVie's strategic expansion into neurology, diversifying its pipeline beyond its traditional dominance in immunology and oncology.

Regarding market performance, ABBV closed at $261.07 (as of July 02, 2026), after reaching a session high of $261.64. Traders are currently assessing broader economic signals, such as the JOLTs Job Openings reported on June 30, which came in at 7.594 million, exceeding forecasts. Such labor market resilience remains a key factor for investors monitoring the stability of large-cap pharmaceutical stocks in the current macro environment.